Radiation Oncology/Epidemiology/Survival
|
Cancer Survival Data
| Disease | Median OS | 1-year OS | 2-year OS | 5-year OS | 10-year OS | ||
|---|---|---|---|---|---|---|---|
| Chordoma | |||||||
| Overall (SEER data) | 6.3 years | 68% | 40% | ||||
| Glioma | |||||||
| Low Grade (WHO II) | |||||||
| RT alone (EORTC 22844) | ~6 years | 59% | |||||
| RT alone (NCCTG) | ~9 years | 94% | 72% | ||||
| Observation (EORTC 22845) | 7.4 years | 66% | |||||
| High Grade (WHO III) | |||||||
| RT alone (RTOG 9402) | 4.7 years | 46% | |||||
| RT alone (EORTC 26951) | 3.4 years | 37% | |||||
| High Grade (WHO IV) | |||||||
| Observation (BTCG 69-01) | 3.2 months | ||||||
| RT alone (BTCG 69-01) | 8.1 months | ||||||
| Pancreas | |||||||
| Resectable | |||||||
| Surgery only (CONKO-001) | 1.7 years | 9% | |||||
| Adjuvant 5FU/RT (GITSG 9173) | 1.7 years | 42% | |||||
| Adjuvant 5FU/RT/Chemo (ESPAC-1) | 1.7 years | ||||||
| Adjuvant GEM-RT/5-FU/GEM (RTOG 9704) | 1.7 years | ||||||
| Adjuvant GEM (CONKO-001) | 1.9 years | 21% | |||||
| Unresectable | |||||||
| No treatment | ~4 months | ||||||
| Palliative bypass | 6-7 months | ||||||
| RT/5-FU (FFCD-SFRO) | 9 months | 32% | |||||
| RT/GEM (ECOG E4201) | 11 months | ||||||
| GEM (FFCD-SFRO) | 13 months | 53% | |||||
| RT/GEM (Taipei) | 14 months | 56% | 15% | ||||
| RT/TNFerade(PACT) | 1.4 years | 71% | |||||
| Prostate | |||||||
| Early Stage (cT1-T2) | |||||||
| Watchful waiting (SPCG-4) | 86% | ||||||
| Surgery (SPCG-4) | 91% | ||||||
| NSCLC | |||||||
| Early Stage Operable | |||||||
| Surgery (Stage I) composite | 65% | ||||||
| Surgery (Stage I) Brazil | 95% | ||||||
| Conventional RT (Stage I) composite | 20% | ||||||
| SBRT (Stage I) Japan | 83% | ||||||
| Surgery (Stage II) | 45% | ||||||
| Spinal Cord Compression | |||||||
| RT Alone (Patchell) | 3 months | ||||||
| Surgery + RT (Patchell) | 4 months | ||||||